Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: Implications for translational research

Despite the introduction of novel effective treatment regimens like gemcitabine plus nab-paclitaxel and FOLFIRINOX, pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive epithelial tumors. | Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma Implications for translational research

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN
TÀI LIỆU MỚI ĐĂNG